drugset / Trial / NCT00254579

Study of CP-675,206 in Refractory Melanoma

NCT00254579 ↗

Phase 2 Completed 251 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelTreatment

Summary

CP-675,206 is a fully human monoclonal antibody (mAb). It binds to the CTLA4 molecule, which is expressed on the surface of activated T lymphocytes. CP-675,206 is thought to stimulate patients' immune systems to attack their tumors. CP-675,206 is not expected to have a direct effect on tumor cells. CP-675,206 been shown to induce durable tumor responses in patients with metastatic melanoma in Phase 1 and Phase 2 clinical studies.

Timeline

Start
2005-12
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Tremelimumab Monoclonal antibody 15 mg/kg —